Cross-Sector entity
Skye Bioscience is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. The clearest coverage concentration is earnings: 1 of 4 stories, with the rest divided among 3 other categories. The tracked stories average 2 original sources each.
4 verified stories tracked
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Skye Bioscience is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. The clearest coverage concentration is earnings: 1 of 4 stories, with the rest divided among 3 other categories. The tracked stories average 2 original sources each. Evolv Technologies appears in 4 tracked Cross-Sector stories from March 9, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Evolv Technologies. Shared-story counts are live from our verified record — not editorial picks.
Expected Earnings Call
Management is expected to discuss financial results and 2026 guidance with analysts.
Earnings Preview Released
Seeking Alpha publishes earnings previews for Evolv Technologies and Skye Bioscience.
Q4 Fiscal Period Ends
Evolv Technologies concludes its fourth quarter of the 2025 fiscal year.
Evolv Technologies is set to report its fourth-quarter 2025 results, with investors focusing on the company's subscription-based revenue growth and AI-driven screening adoption. The report comes amid a broader push for modernized physical security infrastructure across schools, stadiums, and public venues.
Evolv Technologies is set to release its Q4 2025 earnings, a critical milestone for the AI-driven weapons detection firm as it balances rapid deployment with ongoing regulatory scrutiny. The report will serve as a litmus test for the commercial viability of AI-based physical security in high-traffic public venues.
Skye Bioscience is set to report Q4 2025 results as the market eyes progress on its Phase 2 nimacimab trial for obesity. The company's pivot toward the metabolic space positions it as a key player in the next-gen CB1 inhibitor race.
Evolv Technologies and Skye Bioscience are set to report Q4 2025 results, highlighting two critical growth vectors in the healthcare ecosystem: AI-driven physical security and metabolic clinical innovation. While Evolv faces a pivotal moment in hospital infrastructure adoption, Skye’s update will be scrutinized for progress in the competitive obesity therapeutics market.
Source: Seeking Alpha · Seeking Alpha
